Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nanjing Immunophage Raises $14 Million for Novel Immune-Regulating Candidates

publication date: May 5, 2020

Immunophage, a Nanjing biotech, closed a $14 million Pre-A financing, led by Jinfang Hongrui Investment Management, to support its immune-regulating candidates for cancer, autoimmune and neurodegenerative indications. The company's lead cancer projects have dual or multiple anti-tumor properties that pair inhibitors of tumor growth with mechanisms that reverse the tumor's immunosuppressive environment. IPG1094 inhibits tumor growth and the formation of target-mediated myeloid suppressor cells. IPG7236 inhibits tumor metastasis and tumor-related regulatory T cell infiltration. Immunophage's R&D operations are in Shanghai's Caohejing Pujiang High-Tech Park. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital